Global Hemophilia AID project achieves first milestone with donations from Swedish Biotech

13/10/2015 - 3 minutes

The Hemophilia Aid Program has just touched down the first batch of treatments in its target developing countries, as part of a 10-year commitment from US Biogen (Massachusetts) and Swedish Orphan Biovitrum AB (SOBI) from Stockholm via the World Federation of Hemophilia (WFH)’s AID project. The relief effort pledges to ship over 1 billion units of anti-Hemophilia treatments to developing countries to tackle the estimated 300,000 people who do not have access to such medicine.

WFH_logo2015_EN_Much of the Hemophilia Aid Program is contributed to by WHF and Hemophilia for Georgia (another NGO – based in the US as opposed to Canada), which receive clotting factor treatment donations from a range of global sources, including Hemophilia treatment centres (HTCs) and product manufactures such as Swedish Sobi and US Biogen. Started up in 1996, it is by far the largest humanitarian effort to address the rare clotting disease, which is known to affect around 400,000 worldwide (300,000 of which are in the developing world).

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

Support Us

Become a Member